EZH2 and non-small cell lung carcinoma: The medical records of patients diagnosed with NSCLC that were included in the study showed that high levels of EZH2 mRNA expression occurred in 962 of the cases, with a median survival time of 54.17 months; I n 964 cases with low expression, the median survival time was 79.50 months (HR = 1.31, 95% CI 1.15–1.48, p < 0.05).